1cP-LSD vs. 1P-LSD – What We Know, What We Suspect & What the Differences Are

Artsy Shot: Seeing more clearly, understanding more deeply.

This text is for informational purposes and harm reduction. It is not a recommendation, solicitation, or guide—especially not for consumption. With new research chemicals, it is particularly important to remember: The data is scarce, the risks are real, and the legal situation is dynamic.

Executive Summary

1Fe-LSD and 1BP-LSD are the new derivatives in the legal LSD landscape. Never before have two derivatives emerged at once, leading to uncertainty in the community, which we hope to mitigate somewhat with this article. The main difference lies not in the "destination" (which should be familiar to us all), but in the "path": 1Fe-LSD carries a ferrocene residue (iron), 1BP-LSD a boron-containing (boronate) residue. For both, robust human data on pharmacokinetics, metabolites, and long-term risks are lacking; therefore, the greatest uncertainties concern cleavage products, purity, analytics, and legal dynamics. Everything you should know can now be found here.

In recent years, the pattern with LSD derivatives was mostly simple: one derivative disappeared, the next one appeared as a successor. After the discontinuation of 1S-LSD at the end of 2025, the situation is unusual: two new candidates, 1Fe-LSD and 1BP-LSD, are simultaneously on the scene. This leads to confusion, debates, and sometimes contradictory claims.

Therefore, we have tried to compile all currently available information (chemical classification, plausible prodrug mechanism, known/unclear risk factors, legal classification as a snapshot, and community observations) in such a way that you can make an informed, autonomous decision in the club—without marketing bias, without fear-mongering, without false certainties. Important note: With new research chemicals, "plausible" does not equal "proven." We therefore consistently and optimally distinguish between knowledge, well-founded assumption, and open questions.

☝🏻 Disclaimer: Please be sure to note our risk warnings.

Why two new derivatives are suddenly appearing (1Fe-LSD and 1-BP-LSD)

After the inclusion of 1S-LSD in the NpSG (Germany) annex at the end of 2025, the market shifted away from "classic" 1-acyl variants towards structural tricks that not only attach longer carbon chains but also introduce new functional groups into the molecule.

The result (as of January 2026): Two candidates are now being discussed to take over:

• 1Fe-LSD = 1-(Ferrocenecarbonyl)-LSD (organometallic ferrocene residue, contains iron)

• 1BP-LSD = 1-(3-(Tetramethyldioxaborolan)propionyl)-LSD (boronate/boron group in the acyl residue)

Important, because it's constantly confused: 1BP-LSD is not simply "1B-LSD."

• 1B-LSD = 1-butanoyl-LSD (pure carbon acyl residue)

• 1BP-LSD = boronate-containing acyl residue (chemically much more "exotic")

The common core of 1BP-LSD and 1Fe-LSD

For many N¹-acylated lysergamides it is well documented: they bind less well to the target receptors themselves and are hydrolyzed in the body – releasing LSD as the active component.

For 1Fe-LSD, the prodrug narrative is very dominant in the scene and in technical classification: expected cleavage → LSD + ferrocene-carboxylic acid derivative.

For 1BP-LSD, analogously: expected cleavage → LSD + boronate-/boron-containing cleavage product (the exact one depends on actual metabolization).

Radical honesty: "Prodrug-plausible" is not the same as "clinically proven." For both, publicly available, robust human PK/Tox datasets, as one would wish, are lacking – this has also been the case with all previous derivatives, but now even more desirable due to the more complex design of the new derivatives.

Chemistry in one sentence: What is the real difference between the new LSD derivatives?

The differences are not in the "destination" (which should be known to all of us), but in the path to get there:

• 1Fe-LSD carries a ferrocenecarbonyl group (organometallic, contains Fe).

• 1BP-LSD carries a boronate structure (B-chemistry; potentially different hydrolysis/degradation pathways than simple alkyl-acyl residues).

This is precisely the toxicological point that divides the community: "new groups" → new unknowns.

Comparison of the key data of 1Fe-LSD and BP-LSD

Safety & Toxicology: What is plausible – and what is speculation?

1) What is relatively certain (and still doesn't mean "safe")

• LSD itself is pharmacologically well-described – including psychological risks (panic, dysphoria, triggering latent psychoses, etc.).

• For N¹-acyl lysergamides, the prodrug principle is generally strongly supported in the literature.

However, this does not automatically reduce the uncertainty of the cleavage products.

2) 1Fe-LSD: "Iron in the head?" – why this topic is so charged

Why the concern exists: Ferrocene is organometallic; with "iron," alarm bells immediately ring for many (oxidative stress, accumulation, neurodegeneration).

What the more sober counter-position says: In classifications, it is argued that (a) the theoretical amount of iron in typical quantities is in the µg range and (b) the cleavage product is rather polar and is more likely to be excreted.

What must be fairly added: These arguments are chemically plausible, but they do not replace controlled human data (concentration-time profiles, metabolite identity, tissue distribution).

3) 1BP-LSD: "Boron is in medicine – so uncritical?" Unfortunately, too short-sighted

Boron chemistry is not exotic in pharmaceuticals – but: which boron species is formed, how reactive it is, how quickly it is eliminated, and whether there are individual outliers is difficult to assess seriously without data.

In addition, depending on the source/market segment, a second line of discussion often arises here: trust in manufacturing/analytics/transparency (i.e., less "boron theory," more "product reality"). Some community texts therefore classify the situation as a "gray area with uncertainties."

How to frame the decision meaningfully (without deluding oneself)

Instead of "which works better in research?" (which is subjective anyway), the more mature question is:

Axis A: Trust in product quality / analytics

• Who prioritizes: "as traceable origin as possible, as consistent batches as possible" → often tends to 1Fe-LSD in discussions because the manufacturer is framed as a "more known" player.

• Who prioritizes: "I absolutely do not want ferrocene/iron residue" → looks more towards 1BP-LSD, but then accepts the boron unknown.

Axis B: Toxicological gut feeling

• 1Fe-LSD: Fear of "metal residue" vs. counter-argument "quantitatively tiny + rather polar"

• 1BP-LSD: less "metal trigger," but question marks regarding boron-containing cleavage products and, depending on the market segment, regarding the feeling of quality

If one is honest, one concludes: both are bets on plausibility rather than proof, and the decision depends on personal risk preferences.

Harm Reduction Basics that are more important in 2026 than before (because the molecules are "newer")

No how-to, no background info – just the points that can really prevent harm:

• Don't rely on "µg." Derivatives vary in strength – start low, go slow!

• Set & Setting almost always outweigh derivative differences in practice – especially with anxiety and overwhelm during research!

• No polydrug experiments, especially not with stimulants, dissos, or MAO-active substances.

• Take psychological vulnerability seriously (panic, derealization, trigger risk). With a corresponding history, "just don't do it" is the best harm reduction.

Outro

Both 1Fe-LSD and 1BP-LSD do what is expected of them – but they differ in precisely the aspect that drives risk in 2026: cleavage products + data gaps + legal dynamics. 1Fe brings the ferrocene residue (with a well-explainable but not definitively proven all-clear logic), 1BP brings boronate chemistry (pharmacologically not inherently "bad," but also poorly mapped in this context). Anyone seeking an informed decision should look less at myths and more at 1) well-founded information that may still change over the coming months and 2) personal psychological risk factors – and accept that the rest is simply uncertainty for now.

FAQ – Frequently Asked Questions about the comparison of 1Fe-LSD and 1BP-LSD

What is 1Fe-LSD?

1Fe-LSD (often written as 1-FE-LSD) is an N¹-acylated lysergamide. A ferrocenecarbonyl group is attached to the indole nitrogen of LSD (ferrocene = organometallic residue with iron). In discussions, 1Fe-LSD is predominantly classified as a prodrug. In research, it is mainly expected to cleave into LSD and a ferrocene-based cleavage product.

What is 1BP-LSD?

1BP-LSD is also an N¹-acylated lysergamide, where the attached residue is boron-containing (often described as a boronate/boron group). 1BP-LSD is also usually considered a prodrug candidate: the expected main research effect probably results primarily from the release of LSD – plus a boron-containing cleavage product, the toxicological details of which are less well characterized due to a lack of direct data.

Is 1BP-LSD the same as 1B-LSD?

No. This is often confused.

• 1B-LSD is "1-butanoyl-LSD" (classic carbon acyl residue).

• 1BP-LSD refers to a boron-containing (boronate) residue and is chemically a different category.
  This distinction is important for classification, as boron-containing cleavage products can have different properties than pure carbon chains.

What is the difference between 1Fe-LSD and 1BP-LSD?

The core difference lies in the chemical group attached to LSD – and thus in the cleavage products:

• 1Fe-LSD: Ferrocene residue (contains iron)
• 1BP-LSD: boron-containing residue (boronate/boron chemistry)

If both primarily act as LSD derivatives, the "LSD-like" main research effect would be similar for both. Differences (if any) would more likely arise from:

• Hydrolysis rate / onset (how quickly the research effect occurs)
• Cleavage product profile (what exactly is formed, how long it remains, how it is excreted)
• Quality/analytics/manufacturing transparency (product-dependent, not theory-dependent)

Are 1Fe-LSD and 1BP-LSD safe?

One can never say "safe" with new derivatives; this was also true for their predecessors. However, what can be clearly stated is:

• Robust human data (pharmacokinetics, metabolites, controlled toxicology, long-term data) are lacking for both.
• Acute severe physical toxicity is often considered not particularly likely in discussions for very low active substance amounts – but this does not replace data.
• The biggest unknowns are: cleavage products, possible impurities, individual risk profiles (especially psychological), and the legal situation.

Why is "iron in the brain" discussed with 1Fe-LSD?

Because the ferrocene residue contains an iron atom, and "iron" is quickly associated with oxidative stress/neurodegeneration. The opposing view often argues that the potential iron amount is in the microgram range for typical quantities, and the cleavage product is rather polar and excreted. The crucial point remains: these are plausible arguments, but without controlled data, it remains an area of uncertainty.

Why are boron risks discussed with 1BP-LSD?

While boron occurs in medicine, "boron-containing" does not automatically mean "harmless." The critical factors are which boron-containing species is formed, how reactive it is, how quickly it is metabolized/excreted, and whether there are individual outliers. Without data, this also remains an unknown.

What is the legal situation in Germany regarding 1Fe-LSD and 1BP-LSD (as of early 2026)?

As a snapshot from January 2026, neither substance is explicitly listed in the NpSG. However, the legal situation can change rapidly. If you wish to stay updated, please subscribe to our newsletter.

What are the most important points for an informed decision?

To break it down soberly:

1. Accept the data situation: Much is plausible, little is proven.
2. Product reality counts: Analytics, purity, transparency are often more relevant than theoretical debates.
3. Take psychological risks seriously: Set and setting, pre-existing conditions, current stress.

🙏🏻 Feedback: Did you like this article or find it helpful? Do you have praise, criticism, or other feedback? Then we would be immensely grateful for an email to mail@psychedelika.club or a review on Google.